Deep/NN
learning/VBG
for/IN
stage/NN
prediction/NN
in/IN
neuroblastoma/NN
using/VBG
gene/NN
expression/NN
data/NNS
./.
====================
Neuroblastoma/NN
is/VBZ
a/DT
major/JJ
cause/VBP
of/IN
cancer/NN
death/NN
in/IN
early/JJ
childhood/NN
,/,
and/CC
its/PRP$
timely/JJ
and/CC
correct/JJ
diagnosis/NN
is/VBZ
critical/JJ
./.
====================
Gene/NN
expression/NN
datasets/NNS
have/VBP
recently/RB
been/VBN
considered/VBN
as/IN
a/DT
powerful/JJ
tool/NN
for/IN
cancer/NN
diagnosis/NN
and/CC
subtype/NN
classification/NN
./.
====================
However/RB
,/,
no/DT
attempts/NNS
have/VBP
yet/RB
been/VBN
made/VBN
to/TO
apply/RB
deep/NN
learning/VBG
using/VBG
gene/NN
expression/NN
to/TO
neuroblastoma/NN
classification/NN
,/,
although/IN
deep/NN
learning/VBG
has/VBZ
been/VBN
applied/VBN
to/TO
cancer/NN
diagnosis/NN
using/VBG
image/JJ
data/NNS
./.
====================
Taking/VBG
the/DT
International/JJ
Neuroblastoma/NN
Staging/JJ
System/NN
stages/NNS
as/IN
multiple/JJ
classes/NNS
,/,
we/PRP
designed/VBD
a/DT
deep/JJ
neural/JJ
network/NN
using/VBG
the/DT
gene/NN
expression/NN
patterns/NNS
and/CC
stages/NNS
of/IN
neuroblastoma/NN
patients/NNS
./.
====================
Despite/IN
a/DT
small/JJ
patient/NN
population/NN
(/(
n/NN
=/JJ
280/CD
)/)
,/,
stage/NN
1/CD
and/CC
4/CD
patients/NNS
were/VBD
well/RB
distinguished/VBN
./.
====================
If/IN
it/PRP
is/VBZ
possible/JJ
to/TO
replicate/VB
this/DT
approach/NN
in/IN
a/DT
larger/JJR
population/NN
,/,
deep/RB
learning/VBG
could/MD
play/VB
an/DT
important/JJ
role/NN
in/IN
neuroblastoma/NN
staging/NN
./.
====================
In/IN
addition/NN
to/TO
careful/JJ
analyses/NNS
of/IN
clinical/JJ
symptoms/NNS
,/,
numerous/JJ
diagnostic/JJ
methods/NNS
have/VBP
been/VBN
used/VBN
to/TO
diagnose/VB
cancer/NN
[/(
1/CD
]/)
./.
====================
In/IN
particular/JJ
,/,
cancer/NN
is/VBZ
currently/RB
staged/VBD
using/VBG
various/JJ
visual/JJ
methods/NNS
,/,
such/JJ
as/IN
radiography/RB
,/,
computed/VBD
tomography/NN
,/,
bone/NN
scans/NNS
,/,
and/CC
positron/NN
emission/NN
tomography/NN
scans/NNS
[/(
1/CD
]/)
./.
====================
With/IN
the/DT
increasing/VBG
amount/NN
of/IN
available/JJ
data/NNS
from/IN
visual/JJ
images/VBZ
over/IN
recent/JJ
years/NNS
,/,
numerous/JJ
diagnostic/JJ
techniques/NNS
for/IN
cancer/NN
have/VBP
been/VBN
developed/VBN
through/IN
machine/NN
learning/VBG
methods/NNS
such/JJ
as/IN
convolutional/JJ
neural/JJ
networks/NNS
(/(
CNNs/NNS
)/)
[/(
2,3/CD
]/)
./.
====================
Moreover/RB
,/,
methods/NNS
for/IN
improving/VBG
the/DT
performance/NN
of/IN
CNNs/NN
are/VBP
being/VBG
studied/VBN
,/,
and/CC
many/JJ
models/NNS
with/IN
effective/JJ
architectures/NNS
for/IN
classifying/VBG
images/VBZ
have/VBP
been/VBN
developed/VBN
[/(
4/CD
]/)
./.
====================
In/IN
recent/JJ
years/NNS
,/,
categorical/JJ
classification/NN
models/NNS
that/DT
predict/VBP
cancer/NN
stages/NNS
or/CC
types/NNS
of/IN
cancer/NN
have/VBP
been/VBN
constructed/VBN
on/IN
the/DT
basis/NN
of/IN
image/NN
data/NNS
[/(
4,5/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
image/VB
data/NNS
,/,
basic/JJ
classifications/NNS
,/,
such/JJ
as/IN
a/DT
diagnosis/NN
of/IN
cancerous/JJ
versus/CC
healthy/JJ
tissue/NN
,/,
can/MD
be/VB
performed/VBN
through/IN
gene/NN
expression/NN
data/NNS
,/,
and/CC
models/NNS
have/VBP
been/VBN
developed/VBN
using/VBG
traditional/JJ
machine/NN
learning/VBG
methods/NNS
./.
====================
However/RB
,/,
AI-based/JJ
deep/NN
neural/JJ
networks/NNS
(/(
DNNs/NNS
)/)
can/MD
be/VB
developed/VBN
using/VBG
classification/NN
models/NNS
with/IN
data/NNS
matrices/VBZ
of/IN
continuous/JJ
values/NNS
such/JJ
as/IN
expression/NN
data/NNS
./.
====================
Unlike/IN
image/NN
data/NNS
,/,
genomic/JJ
data/NNS
can/MD
be/VB
used/VBN
as/IN
a/DT
proxy/JJ
for/IN
the/DT
early/JJ
diagnosis/NN
of/IN
cancer/NN
,/,
meaning/VBG
that/DT
models/NNS
based/VBN
on/IN
gene/NN
expression/NN
data/NNS
can/MD
also/RB
be/VB
useful/JJ
for/IN
identifying/VBG
or/CC
predicting/VBG
the/DT
diagnosis/NN
or/CC
progression/NN
of/IN
cancer/NN
and/CC
for/IN
providing/VBG
timely/RB
and/CC
appropriate/JJ
cancer/NN
treatment/NN
[/(
6/CD
]/)
./.
====================
However/RB
,/,
to/TO
construct/VB
a/DT
DNN/JJ
model/NN
,/,
a/DT
sufficient/JJ
dataset/NN
is/VBZ
required/VBN
[/(
7/CD
]/)
./.
====================
Although/IN
data/NNS
can/MD
be/VB
obtained/VBN
individually/RB
,/,
it/PRP
is/VBZ
possible/JJ
to/TO
secure/VB
a/DT
sufficiently/RB
large/JJ
dataset/NN
to/TO
build/JJ
a/DT
model/NN
through/IN
the/DT
Gene/NN
Expression/NN
Omnibus/FW
(/(
GEO/NN
)/)
[/(
8/CD
]/)
and/CC
The/DT
Cancer/NN
Genome/NN
Atlas/IN
(/(
TCGA/NN
)/)
[/(
9/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
furnishing/JJ
genomic/JJ
data/NNS
,/,
these/DT
sources/NNS
also/RB
provide/VBP
data/NNS
indicating/VBG
patients/NNS
â€™/CD
medical/JJ
status/NN
,/,
allowing/VBG
us/PRP
to/TO
examine/VB
the/DT
correlations/NNS
between/IN
clinical/JJ
variables/NNS
and/CC
specific/JJ
genomic/JJ
data/NNS
of/IN
interest/NN
[/(
8,9/CD
]/)
./.
====================
Neuroblastoma/NN
is/VBZ
an/DT
extracranial/JJ
solid/JJ
tumor/NN
that/DT
most/JJS
commonly/RB
occurs/VBZ
in/IN
childhood/NN
[/(
10,11/CD
]/)
./.
====================
The/DT
specific/JJ
traits/NNS
of/IN
neuroblastoma/NN
include/VBP
its/PRP$
early/JJ
age/NN
of/IN
onset/NN
,/,
a/DT
tendency/NN
for/IN
spontaneous/JJ
regression/NN
of/IN
the/DT
tumor/NN
in/IN
infancy/NN
,/,
and/CC
the/DT
high/JJ
frequency/NN
of/IN
metastatic/JJ
disease/NN
at/IN
diagnosis/NN
[/(
10/CD
]/)
./.
====================
Neuroblastoma/NN
is/VBZ
staged/VBN
using/VBG
the/DT
International/JJ
Neuroblastoma/NN
Staging/JJ
System/NN
(/(
INSS/NN
)/)
[/(
12/CD
]/)
./.
====================
This/DT
system/NN
classifies/VBZ
tumors/NNS
in/IN
terms/NNS
of/IN
their/PRP$
appearance/NN
upon/IN
an/DT
analysis/NN
of/IN
surgical/JJ
biopsy/NN
findings/NNS
,/,
but/CC
this/DT
staging/VBG
system/NN
alone/RB
can/MD
not/RB
help/VB
doctors/VBZ
to/TO
determine/VB
a/DT
plan/JJ
for/IN
neuroblastoma/NN
treatment/NN
,/,
since/IN
it/PRP
is/VBZ
dependent/JJ
upon/IN
surgical/JJ
biopsy/NN
findings/NNS
and/CC
its/PRP$
results/NNS
are/VBP
obtained/VBN
post-surgery/RB
[/(
12,13/CD
]/)
./.
====================
However/RB
,/,
as/IN
increasing/VBG
amounts/NNS
of/IN
data/NNS
on/IN
neuroblastoma/NN
have/VBP
become/VBN
available/JJ
,/,
and/CC
suitable/JJ
genomic/JJ
data/NNS
can/MD
be/VB
obtained/VBN
from/IN
public/JJ
databases/NNS
(/(
e.g./FW
,/,
GEO/NN
and/CC
TCGA/NN
)/)
,/,
it/PRP
is/VBZ
now/RB
possible/JJ
to/TO
explore/VB
whether/IN
a/DT
correlation/NN
exists/VBZ
between/IN
INSS/NN
stages/NNS
and/CC
genomic/JJ
traits/VBZ
such/JJ
as/IN
the/DT
mutation/NN
profile/NN
or/CC
gene/NN
expression/NN
data/NNS
[/(
14/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
in/IN
order/NN
to/TO
identify/VB
such/JJ
correlations/NNS
,/,
we/PRP
developed/VBD
a/DT
simple/JJ
DNN/NN
model/NN
using/VBG
a/DT
data/NNS
set/VBP
of/IN
neuroblastoma/NN
patients/NNS
including/VBG
gene/NN
expression/NN
data/NNS
and/CC
clinical/JJ
data/NNS
(/(
i.e./FW
,/,
INSS/NN
stages/NNS
)/)
./.
====================
We/PRP
investigated/VBD
whether/IN
our/PRP$
DNN/NN
model/NN
with/IN
gene/NN
expression/NN
data/NNS
could/MD
classify/VB
the/DT
INSS/NN
stages/NNS
./.
====================
Dataset/NN
and/CC
data/NNS
handling/NN
====================
As/IN
a/DT
public/JJ
neuroblastoma/NN
dataset/NN
,/,
we/PRP
downloaded/VBD
accession/NN
GSE85047/NN
[/(
15/CD
]/)
from/IN
the/DT
GEO/NN
database/NN
(/(
https/NNS
:/:
//www.ncbi.nlm.nih.gov/geo//JJ
)/)
./.
====================
GSE85047/NN
contains/VBZ
280/CD
samples/NNS
of/IN
neuroblastoma/NN
clinical/JJ
data/NNS
and/CC
the/DT
data/NNS
matrix/VBP
includes/VBZ
INSS/NN
stage/NN
and/CC
expression/NN
array/NN
data/NNS
./.
====================
An/DT
expression/NN
array/NN
was/VBD
performed/VBN
using/VBG
an/DT
Affymetrix/JJ
Human/JJ
Exon/NN
1.0/CD
ST/NN
Array/NN
(/(
Affymetrix/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NN
)/)
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
INSS/NN
stages/NNS
(/(
1/CD
,/,
2/CD
,/,
3/CD
,/,
4/CD
,/,
and/CC
4S/NN
)/)
were/VBD
considered/VBN
as/IN
classes/NNS
./.
====================
In/IN
order/NN
to/TO
convert/VB
the/DT
array/NN
ID/NN
into/IN
the/DT
HUGO/NN
gene/NN
symbol/NN
,/,
we/PRP
used/VBD
the/DT
GPL5175/NN
probe-gene/NN
symbol/NN
mapping/NN
annotation/NN
file/JJ
./.
====================
Next/RB
,/,
we/PRP
edited/VBD
the/DT
matrix/NN
containing/VBG
only/RB
INSS/NN
stage/NN
and/CC
gene/NN
expression/NN
array/NN
data/NNS
for/IN
data/NNS
feeding/VBG
into/IN
the/DT
DNN/NN
architecture/NN
./.
====================
The/DT
data/NNS
matrix/VBP
was/VBD
280/CD
patients/NNS
by/IN
13,091/CD
gene/NN
symbols/NNS
./.
====================
We/PRP
split/VBP
this/DT
data/NNS
matrix/VBP
into/IN
a/DT
training/JJ
set/NN
and/CC
test/VB
set/NN
at/IN
a/DT
ratio/NN
of/IN
8:2/CD
,/,
using/VBG
scikit-learn/NN
train_test_split/VBP
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Model/NN
construction/NN
and/CC
validation/NN
====================
To/TO
construct/VB
our/PRP$
DNN/NN
model/NN
,/,
we/PRP
utilized/VBD
TensorFlow/NN
1.13.1/CD
as/IN
our/PRP$
machine/NN
learning/VBG
library/NN
with/IN
Python/NN
3.6.0/CD
[/(
16/CD
]/)
./.
====================
We/PRP
chose/VBP
tf.contrib.learn.DNNClassifier/NN
for/IN
model/NN
construction/NN
./.
====================
For/IN
the/DT
hyperparameters/NNS
of/IN
our/PRP$
model/NN
,/,
we/PRP
set/VBP
the/DT
dropout/NN
rate/NN
at/IN
0.15/CD
,/,
we/PRP
chose/VBP
the/DT
Adam/NN
optimizer/RB
,/,
and/CC
we/PRP
fixed/VBD
the/DT
learning/VBG
rate/NN
at/IN
1e-5/CD
./.
====================
The/DT
activation/NN
function/NN
was/VBD
leaky_relu/RBR
and/CC
the/DT
number/NN
of/IN
layers/NNS
was/VBD
4/CD
./.
====================
The/DT
numbers/NNS
of/IN
neurons/NNS
of/IN
the/DT
layers/NNS
were/VBD
512/CD
,/,
256/CD
,/,
128/CD
,/,
and/CC
16/CD
,/,
respectively/RB
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
When/WRB
we/PRP
constructed/VBD
our/PRP$
model/NN
under/IN
these/DT
hyperparameter/NN
settings/NNS
,/,
we/PRP
set/VBP
the/DT
number/NN
of/IN
learning/VBG
steps/NNS
as/IN
5,000/CD
./.
====================
An/DT
Nvidia/NN
Titan/NN
RTX/NN
24GB/NN
was/VBD
used/VBN
for/IN
the/DT
GPU/NN
./.
====================
In/IN
order/NN
to/TO
obtain/VB
measurements/NNS
for/IN
the/DT
performance/NN
of/IN
our/PRP$
model/NN
,/,
accuracy/NN
was/VBD
calculated/VBN
using/VBG
the/DT
predicted/VBN
values/NNS
from/IN
the/DT
training/VBG
set/NN
and/CC
the/DT
test/NN
set/NN
;/:
then/RB
,/,
receiver/RB
operating/VBG
characteristic/JJ
curves/NNS
and/CC
the/DT
area/NN
under/IN
the/DT
curve/JJ
(/(
AUC/NN
)/)
were/VBD
obtained/VBN
by/IN
the/DT
roc-curve/NN
function/NN
in/IN
the/DT
scikit-learn/NN
package/NN
./.
====================
After/IN
5,000/CD
iterations/NNS
with/IN
the/DT
training/VBG
set/NN
,/,
the/DT
accuracy/NN
was/VBD
calculated/VBN
from/IN
each/DT
training/VBG
set/NN
and/CC
test/VB
set/NN
,/,
with/IN
values/NNS
of/IN
100/CD
%/NN
and/CC
55.56/CD
%/NN
,/,
respectively/RB
./.
====================
In/IN
the/DT
training/VBG
set/NN
,/,
the/DT
macro-average/NN
AUC/NN
,/,
micro-average/NN
AUC/NN
,/,
and/CC
all/DT
the/DT
AUC/NN
values/NNS
for/IN
one-versus-rest/JJS
(/(
OVR/NN
)/)
decisions/NNS
were/VBD
all/DT
1/CD
(/(
Fig/NN
./.
====================
3A/NN
)/)
./.
====================
In/IN
the/DT
test/NN
set/NN
,/,
we/PRP
observed/VBD
a/DT
macro-average/JJ
AUC/NN
of/IN
0.71/CD
,/,
and/CC
a/DT
micro-average/JJ
AUC/NN
of/IN
0.77/CD
for/IN
five-class/CD
classification/NN
and/CC
prediction/NN
using/VBG
our/PRP$
model/NN
./.
====================
The/DT
OVR/NN
AUCs/NNS
for/IN
stages/NNS
(/(
equivalently/RB
,/,
classes/NNS
)/)
1/CD
,/,
2/CD
,/,
3/CD
,/,
4/CD
and/CC
4S/NN
were/VBD
0.8/CD
,/,
0.66/CD
,/,
0.59/CD
,/,
0.85/CD
,/,
and/CC
0.58/CD
,/,
respectively/RB
(/(
Fig/NN
./.
====================
3B/NN
)/)
./.
====================
Overall/RB
,/,
we/PRP
observed/VBD
that/IN
our/PRP$
model/NN
predicted/VBN
stage/NN
1/CD
and/CC
4/CD
patients/NNS
well/RB
./.
====================
From/IN
these/DT
results/NNS
,/,
we/PRP
could/MD
distinguish/VB
stages/NNS
1/CD
and/CC
4/CD
in/IN
neuroblastoma/NN
patients/NNS
./.
====================
Considering/VBG
the/DT
poor/JJ
prediction/NN
of/IN
the/DT
other/JJ
stages/NNS
in/IN
the/DT
test/NN
set/NN
,/,
it/PRP
is/VBZ
likely/JJ
that/IN
overfitting/VBG
occurred/VBD
for/IN
stages/NNS
2/CD
,/,
3/CD
,/,
and/CC
4S/NN
./.
====================
Alternatively/RB
,/,
there/EX
may/MD
be/VB
no/DT
distinguishable/JJ
genes/NNS
between/IN
stages/NNS
2/CD
,/,
3/CD
,/,
and/CC
4S/NN
in/IN
terms/NNS
of/IN
gene/NN
expression/NN
./.
====================
Our/PRP$
study/NN
was/VBD
performed/VBN
using/VBG
data/NNS
from/IN
a/DT
relatively/RB
small/JJ
number/NN
of/IN
patients/NNS
(/(
280/CD
cases/NNS
)/)
./.
====================
Increasing/VBG
the/DT
number/NN
of/IN
patients/NNS
to/TO
the/DT
order/NN
of/IN
103/CD
or/CC
104/CD
would/MD
be/VB
appropriate/JJ
,/,
since/IN
successful/JJ
DNN/NN
construction/NN
requires/VBZ
several/JJ
thousand/DT
labeled/VBN
cases/NNS
in/IN
biological/JJ
problems/NNS
[/(
7,17/CD
]/)
./.
====================
Overview/NN
of/IN
our/PRP$
model/NN
./.
====================
Our/PRP$
model/NN
utilized/VBD
a/DT
simple/JJ
deep/NN
neural/JJ
network/NN
architecture/NN
with/IN
GSE85047/NN
gene/NN
expression/NN
data/NNS
./.
====================
The/DT
classes/NNS
are/VBP
the/DT
International/JJ
Neuroblastoma/NN
Staging/JJ
System/NN
stage/NN
of/IN
each/DT
patient/NN
from/IN
GSE85047/NN
./.
====================
False/NN
positive/JJ
rate/NN
(/(
FPR/NN
)/)
,/,
it/PRP
is/VBZ
the/DT
calculated/JJ
number/NN
of/IN
predicted/VBN
false/VBP
positives/VBZ
divided/VBN
by/IN
the/DT
total/JJ
number/NN
of/IN
negatives/NNS
in/IN
the/DT
test/NN
set/NN
./.
====================
;/:
true/JJ
positive/JJ
rate/NN
(/(
TPR/NN
)/)
,/,
it/PRP
is/VBZ
obtained/VBN
as/IN
the/DT
number/NN
of/IN
predicted/VBN
true/JJ
positives/VBZ
divided/VBN
by/IN
the/DT
total/JJ
number/NN
of/IN
positives/VBZ
in/IN
the/DT
test/NN
set/NN
./.
====================
Deep/NN
neural/JJ
network/NN
architecture/NN
of/IN
our/PRP$
model/NN
./.
====================
Model/NN
performance/NN
./.
====================
(/(
A/DT
)/)
Receiver/RB
operating/VBG
characteristic/JJ
(/(
ROC/NN
)/)
curves/VBZ
and/CC
the/DT
area/NN
under/IN
the/DT
ROCs/NNS
(/(
AUROCs/NNS
)/)
of/IN
micro-/JJ
,/,
macro-/JJ
,/,
and/CC
one-versus-rest/IN
(/(
OVR/NN
)/)
decisions/NNS
obtained/VBN
from/IN
the/DT
training/VBG
set/NN
./.
====================
(/(
B/NN
)/)
The/DT
ROC/NN
curves/NNS
and/CC
the/DT
AUROCs/NNS
of/IN
micro-/JJ
,/,
macro-/JJ
,/,
and/CC
OVR/NN
decisions/NNS
obtained/VBN
from/IN
the/DT
test/NN
set/NN
./.
====================
